About Us

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

History

Kyowa Hakko Kirin is a pharmaceutical company, formed from a combination of the depth of experience and strong business record of Kyowa Hakko and Kirin Pharma.
Find out the combined histories of Kyowa Hakko (icon: icon of Kyowa Hakko) and Kirin Pharma (icon: icon of Kirin Pharma), followed by the history of Kyowa Hakko Kirin, touching upon their performance in the field of research and development to date.

Year History
1885 Foundation of the Japan Brewery Company, the origin of Kirin Brewery Company, Limited.
1907 Establishment of Kirin Brewery Co., Ltd.
1944 Initiation of fermentative alcohol (absolute alcohol) manufacturing.
1948 Initiation of Japan's first mass production of acetone butanol from syrup (beginning of involvement in chemical business operations).
1949 Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.
1951 Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).
1956 Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.
Invention of the process of L-glutamic acid production by fermentation (a world first).
1958 Invention of the process of L-lysine production by fermentation.
1963 Initiation of full-scale involvement in the pharmaceutical business.
Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.
1967 Release of 5-FU, an anticancer drug, and Acetylspiramycin, an antibiotic drug.
1969 Establishment of Kyowa Hakko U.S.A., Inc.
Establishment of Pharmaceutical Research Institute.
1971 Release of Leunase, an anticancer drug.
1973 Establishment of Kyowa Hakko Europe GmbH.
Released of the cell-wall-digesting enzyme Zymolyase® as a research reagent.
1975 Release of Depakene, an anti-epileptic drug.
Release of Determiner TC・FC, a diagnostic reagent.
1976 Development of malt diastase as a commercial digestive aid.
1978 Release of Glumal, a drug for digestive ulcer.
Release of Inovan, an agent to improve acute circulatory failure.
Year History
1981 Establishment of the Clinical Reagents Division as an independent company, Kyowa Medex Co., Ltd.
1982 The first real move into the pharmaceuticals business was made with a reorganization of research and development, involving the establishment of a new R&D Division in Head Office.
The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.
Release of Sagamicin, an aminoglycoside antibiotics.
Release of Nauzelin, a gastrointestinal drug.
1984 Establishment of Kirin-Amgen, Inc.
1985 Release of Fortimicin, an aminoglycoside antibiotics.
1986 Agreement with Sankyo Co., Ltd (Now the Daiichi Sankyo Company, Limited) on development, manucafcuring and marketing ESPO®
1987 Release of Celtect, an anti-allergic drug.
1988 Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).
Establishment of Gemini Science, Inc. in the U.S.A.
Establishment of Kato Memorial Bioscience Foundation.
1989 Release of Acenalin, a gastroprokinetic drug.
1990 Release of ESPO®, an erythropoietin (EPO) drug.
Establishment of Medical Representative Offices in New York and Düsseldorf, as pharmaceuticals development base.
1991 Release of GRAN®, G-CSF drug.
Establishment of Jeil-Kirin Pharmaceutical Inc.
Release of Depakene R, an anti-epileptic drug.
Release of Activacin, a thrombolytic agent.
Release of Coniel, a remedy for hypertension and agina pectoris.
1992 Establishment of Kyowa Pharmaceutical, Inc. in the USA.
1993 Establishement of Kirin Pharmaceutical (Asia) Co., Ltd.
Year History
1994 Release of Neu-up, a recombinant human G-CSF derivative as an anti-neutropenia.
Release of Determiner HDL-C, a diagnostic reagent for HDL cholesterol.
1997 Establishment of Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.
Release of Imagenil, a non-ionic X-ray contrast medium.
1998 Initiation of the marketing of Navoban, an oral anti-emetic.
1999 Release of Navelbine, an anticancer drug.
Determination of the whole genome sequence of Corynebacterium glutamicum.
Release of Meditransnitro, a transdermal nitroglycerin product.
2000 Establishment of technology for human antibody generating mice.
Development of the commercial production process of oligosaccharides by fermentation.
2001 Release of Rocaltrol®, a medicine for secondary hyperparathyroidism.
Release of ALLELOCK®, an anti-allergic drug.
Development of an innovative antibody technology (POTELLIGENT®) that enhance antibody activity.
2002 Release of GRAN® syringe, a drug for neutropenia.
2003 Release of ESPO® syringe, a drug for renal anemia.
Release of PHOSBLOCK®, a drug for hyperphosthatemia.
Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.
Release of Desmopressin Spray 10 Kyowa, a treatment for nocturnal enuresis.
2004 Development of a new method for industrially producing di-peptides, which consist of a pair of amino acids.
Year History
2005 Establishment of Kirin Pharmaceutical Singapore Pte., Ltd.
Establishement of Kirin Pharmaceutical (Thailand) Co., Ltd.
Completion of the transition to an operating holding company; pharmaceuticals and bio-chemicals are its main pillars.
2006 Release of Patanol, an anti-allergic eye drops.
Release of Bothdel, an MRI contrast medium for the gastrointestinal tract.
Development of the process of L-tyrosine mass production by fermentation (a world first).
2007 The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system.
Release of NESP®, a long-acting erythropoietic stimulating drug.
Announced a strategic alliance between Kyowa Hakko Group and Kirin Group.
Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.
Release of the anti-epileptic drug Topina.
2008 Release of REGPARA®, a drug for secondary hyperparathyroidism.
Capital alliance between Kyowa Hakko Group and Kirin Group.
Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.
Year History
2008 Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko and Kirin Pharma.
2009 Introduced "Commitment to Life".
2010 Completion of One of Japan's leading facilities for producing investigational therapeutic antibodies on the Bio Process Research and Development Laboratories.
Completion of the new research buildings on the Tokyo Research Park.
2011 Sold all shares of equity method affiliate Kirin Kyowa Foods Company, Limited to Kirin Holdings Company, Limited.
Sold all shares of Kyowa Hakko Chemical Co., Ltd. to KJ Holdings Inc.
Acquired ProStrakan Group plc.
2012 Establishment of FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., a Joint-Venture of FUJIFILM and Kyowa Hakko Kirin for the development, manufacturing and sales of biosimilars
Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. change its name to "Kyowa Hakko Kirin China Pharmaceutical Co., Ltd."
JEIL-KIRIN PHARMACEUTICAL INC. change its name to "Kyowa Hakko Kirin Korea Co., Ltd."
Launch of POTELIGEO® (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
Strategic alliance between Otsuka Pharmaceutical and Kyowa Hakko Kirin in the fields of diabetes and oncology
Establishment of a Subsidiary in Thailand
Construction of a New Facility for Formulation of Solid Dosage Forms at the Ube Plant
Year History
2013 Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent
Launch of Onglyza® Tablets 2.5mg, 5mg in Japan, for Type 2 Diabetes
Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia
Establishment of Singapore Translational Research Laboratory
2014 Launch of Long-Acting Erythropoiesis-Stimulating Agent NESP® Injection 5 μg Plastic Syringe in Japan
ProStrakan Completes Acquisition of Archimedes
Launch of Dovobet® Ointment Topical Combination Drug for Psoriasis Vulgaris
Completion of Construction for Drug Product Manufacturing Facility in the Takasaki Plant
Launch of Sustained-Duration G-CSF Product G-Lasta® in Japan
2015 Completion of Construction for New Research Building in Fuji Research Park
Launch of REGPARA® Tablets 12.5mg in Japan,a drug for secondary hyperparathyroidism
Approval for recombinant human antithrombin preparation ACOALAN® injection in Japan
Option agreement with AstraZeneca for commercialisation of Benralizumab (KHK4563) in Japan
Year History
2016 Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin"
Completion of Construction for Biopharmaceutical API Manufacturing Facility in the Takasaki Plant
Launch of LUMICEF® for Psoriasis Treatment in Japan

To Page Top